Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a …

M Gharbiya, F Parisi, F Cruciani, F Bozzoni-Pantaleoni… - Retina, 2014 - journals.lww.com
M Gharbiya, F Parisi, F Cruciani, F Bozzoni-Pantaleoni, F Pranno, S Abdolrahimzadeh
Retina, 2014journals.lww.com
Purpose: To evaluate long-term outcome of intravitreal anti–vascular endothelial growth
factor monotherapy in retinal angiomatous proliferation. Methods: Twenty-one treatment-
naive eyes were included in this prospective, interventional case series. Treatment was
three monthly injections of bevacizumab and/or ranibizumab with a modified PrONTO-style
regimen. Best-corrected visual acuity (BCVA) was evaluated. The influence of baseline
BCVA and pretreatment pigment epithelial detachment on BCVA outcome or retreatment …
Purpose:
To evaluate long-term outcome of intravitreal anti–vascular endothelial growth factor monotherapy in retinal angiomatous proliferation.
Methods:
Twenty-one treatment-naive eyes were included in this prospective, interventional case series. Treatment was three monthly injections of bevacizumab and/or ranibizumab with a modified PrONTO-style regimen. Best-corrected visual acuity (BCVA) was evaluated. The influence of baseline BCVA and pretreatment pigment epithelial detachment on BCVA outcome or retreatment were assessed by Pearson correlation analysis.
Results:
Results were evaluated at 2 years and 3 years for 21 and 13 eyes, respectively. Mean baseline BCVA improved significantly from 44.5 (±11.0)(20/32) to 51.1 (±9.7)(20/24) and 50.8 (±10.4) letters (20/24) at 2 and 3 years, respectively (P= 0.02 and P= 0.049). Pigment epithelial detachment correlated negatively with BCVA outcome (r=− 0.65, P= 0.002 and r=− 0.67, P= 0.01 at 2 years and 3 years, respectively) and was significantly associated with retreatment (r= 0.62, P= 0.003 and r= 0.87, P< 0.0001 at 2 years and 3 years, respectively). Complete occlusion of the lesion was obtained in 71% and 69% of eyes at 2 years and 3 years, respectively, with a mean of 9.4 injections at 3 years.
Conclusion:
Intravitreal anti–vascular endothelial growth factor monotherapy was a valid option for retinal angiomatous proliferation. Stable or improved visual acuity was obtained in 95% and 100% of eyes at 2 years and 3 years, respectively.
Lippincott Williams & Wilkins